DRRX
Price:
$1.01
Market Cap:
$31.35M
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2000-09-28
Stock Exchange
NASDAQ
Ticker
DRRX
According to DURECT Corporation’s latest financial reports and current stock price. The company's current ROE is -232.73%. This represents a change of 76.52% compared to the average of -131.85% of the last 4 quarters.
The mean historical ROE of DURECT Corporation over the last ten years is -133.06%. The current -232.73% ROE has changed 74.90% with respect to the historical average. Over the past ten years (40 quarters), DRRX's ROE was at its highest in in the June 2017 quarter at 540.10%. The ROE was at its lowest in in the September 2024 quarter at -352.10%.
Average
-133.06%
Median
-123.01%
Minimum
-413.88%
Maximum
-6.29%
Discovering the peaks and valleys of DURECT Corporation ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 949.49%
Maximum Annual ROE = -6.29%
Minimum Annual Increase = -95.85%
Minimum Annual ROE = -413.88%
Year | ROE | Change |
---|---|---|
2023 | -186.86% | 31.20% |
2022 | -142.42% | 115.85% |
2021 | -65.98% | 949.49% |
2020 | -6.29% | -93.69% |
2019 | -99.69% | -21.27% |
2018 | -126.61% | 636.29% |
2017 | -17.20% | -95.85% |
2016 | -413.88% | 171.80% |
2015 | -152.27% | 27.52% |
2014 | -119.42% | 71.01% |
The current ROE of DURECT Corporation (DRRX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-131.76%
5-year avg
-100.25%
10-year avg
-133.06%
DURECT Corporation’s ROE is greater than Shuttle Pharmaceuticals Holdings, Inc. (-582.98%), greater than Mallinckrodt plc (-74.45%), greater than Organogenesis Holdings Inc. (-2.69%), greater than Lucy Scientific Discovery Inc. (-296.96%), greater than Alimera Sciences, Inc. (-33.70%), greater than Alpha Teknova, Inc. (-37.32%), less than Agile Therapeutics, Inc. (104.04%), greater than Sonoma Pharmaceuticals, Inc. (-63.67%), less than Eagle Pharmaceuticals, Inc. (17.39%), less than Lifecore Biomedical, Inc. (17.23%), greater than RedHill Biopharma Ltd. (-103.24%), less than Taro Pharmaceutical Industries Ltd. (3.05%), less than Collegium Pharmaceutical, Inc. (40.81%), less than Neurocrine Biosciences, Inc. (15.68%), greater than Deciphera Pharmaceuticals, Inc. (-52.42%), greater than Ironwood Pharmaceuticals, Inc. (-7.63%), less than Alkermes plc (26.49%), greater than Avadel Pharmaceuticals plc (-93.32%), less than Aquestive Therapeutics, Inc. (62.93%), greater than Evoke Pharma, Inc. (-308.51%), less than Adamis Pharmaceuticals Corporation (0.33%), less than Guardion Health Sciences, Inc. (77.24%), greater than AcelRx Pharmaceuticals, Inc. (-39.88%),
Company | ROE | Market cap |
---|---|---|
-582.98% | $3.19M | |
-74.45% | $4.52M | |
-2.69% | $536.94M | |
-296.96% | $906.91K | |
-33.70% | $301.29M | |
-37.32% | $390.75M | |
104.04% | $10.43M | |
-63.67% | $3.82M | |
17.39% | $12.31M | |
17.23% | $269.21M | |
-103.24% | $8.25M | |
3.05% | $1.62B | |
40.81% | $966.22M | |
15.68% | $12.72B | |
-52.42% | $2.21B | |
-7.63% | $550.50M | |
26.49% | $4.66B | |
-93.32% | $1.12B | |
62.93% | $415.77M | |
-308.51% | $6.43M | |
0.33% | $7.25M | |
77.24% | $4.35M | |
-39.88% | $14.58M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like DURECT Corporation using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like DURECT Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is DURECT Corporation's ROE?
How is the ROE calculated for DURECT Corporation (DRRX)?
What is the highest ROE for DURECT Corporation (DRRX)?
What is the 3-year average ROE for DURECT Corporation (DRRX)?
What is the 5-year average ROE for DURECT Corporation (DRRX)?
How does the current ROE for DURECT Corporation (DRRX) compare to its historical average?